Related Experiment Video
Updated: Jan 29, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Anticoagulation in atrial fibrillation and cognitive decline: A systematic review and meta-analysis
Decai Zeng1, ChunLan Jiang, Chunxiao Su
1Department of Ultrasonic Medicine, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Insights
Anticoagulation significantly reduces the risk of cognitive decline in atrial fibrillation (AF) patients, independent of stroke or TIA. However, it offers no additional benefit over antiplatelet therapy for cognitive protection.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) is a known risk factor for cognitive decline, independent of stroke.
- The role of anticoagulation in mitigating this cognitive risk in AF patients remains debated.
Purpose of the Study:
- To systematically review and meta-analyze the effect of anticoagulation on cognitive decline risk in AF patients.
Main Methods:
- Searched PubMed, Embase, and Cochrane databases up to January 2018.
- Extracted risk ratios (RR) and 95% confidence intervals (CI) for cognitive decline.
- Pooled estimations using a fixed-effects model and performed subgroup analyses.
Main Results:
- Included 8 studies with 454,273 patients.
- Anticoagulation showed a reduced risk of cognitive impairment (RR 0.72, 95% CI 0.69-0.75).
- This benefit persisted after adjusting for stroke and TIA, but was not superior to antiplatelet treatment (RR 1.01, 95% CI 0.68-1.50).
Conclusions:
- Anticoagulation provides cognitive benefits in AF patients, independent of stroke and TIA.
- Anticoagulant therapy is not superior to antiplatelet drugs in reducing cognitive decline risk.
Background:
It is well known that atrial fibrillation (AF) carried a high risk of cognitive decline, which is independent of stroke or transient ischemic attack (TIA). Whether anticoagulation is associated with reduced risk of cognitive decline in participants with AF still remains controversial. We conducted a systematic review and meta-analysis to explore the effect of anticoagulation on the risk of cognitive decline in patients with AF.
Methods:
We systematically searched the PubMed, Embase and the Cochrane Database for eligible studies published up to January 2018. Risk ratios (RR) with 95% confidence interval (CI) for cognitive decline were extracted, and pooled estimations were calculated using the fixed effects model. Subgroup analyses were further performed.
Results:
Eight relevant articles involved 454,273 patients were ultimately included in this meta-analysis. We found that anticoagulation was associated with reduced risk of cognitive impairment as compared with nonanticoagulation (RR 0.72, 95% CI 0.69-0.75, I 11.5%). This reduction was still significant after adjustment for stroke and TIA (RR 0.72, 95% CI 0.69-0.74, I 0.0%). In the subgroup analyses, the incidence of cognitive decline was significantly decreased in those treated with anticoagulation compared to no treatment (RR 0.72, 95% CI 0.69-0.75, I 0.0%), but the cognitive benefit showed no significant difference between anticoagulant and antiplatelet treatment (RR 1.01, 95% CI 0.68-1.50, I 46.8%).
Conclusion:
Anticoagulation is associated with cognitive benefit in participants with AF independent of stroke and TIA, but it was not superior to antiplatelet drugs in reducing the risk of cognitive decline.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Magnetic Declination
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview

